

Amendments to the Specification

Please replace original Figures 14, 18, 19, 26, 27, and 28 with the substitute Figures 14, 18, 19, 26, 27, and 28 submitted herewith.

Please replace the paragraph at page 6, lines 14-15 with the following amended paragraph: Figures 14A-14J are the nucleic acid sequence of pD17-cJ-dCH2.H1 (SEQ ID NO: 10), the plasmid shown in Figure 5, chimeric BR96 having the CH2 deletion.

Please replace the paragraph at page 6, line 24 with the following amended paragraph: Figures 18A-18F are the nucleic acid sequence of pD17-hJm14.H1 (SEQ ID NO: 22).

Please replace the paragraph at page 6, line 26 with the following amended paragraph: Figures 19A-19N are the nucleic acid sequence of pD17-hG1b (SEQ ID NO: 23).

Please replace the paragraph at page 10, lines 8-15 with the following amended paragraph: As used herein the ~~terms~~ term “multiple toxicity associated domains” or “multiple toxicity associated regions” means more than one discrete toxicity associated domain or region. As there appear to be at least two toxicity associated domains or regions in the immunoglobulin molecule, one roughly localized to amino acids 231-238 and the other roughly localized to amino acids 310-331, an example of the structural alteration of multiple toxicity associated domains or regions comprises the insertion, substitution or deletion of amino acid residues in both of these domains or regions. This definition excludes structural alterations targeting a single toxicity associated domain or region.